News – Page 1036 – Endpoints News

ASCO looming, Loxo, Bayer line up a quick shot at FDA OK for their groundbreaking approach to cancer therapy

8 years ago

Eidos, Avrobio shoot for $201M as biotech IPOs continue to roll forward on Nasdaq

8 years ago

Genmab takes a hit after J&J sounds retreat on cancer combos, as patient deaths force researches to scrap trials

8 years ago

Roche's Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, ...

8 years ago

CRI report tracks explosive growth of cell therapies in the global pipeline, as China researchers muscle toward the ...

8 years ago

Ex-Gilead R&D chief Bischofberger starts over as CEO of Kronos Bio; Sue Mahony steps down from Lilly Oncology

8 years ago

Kezar and Xeris file for IPOs, joining May's march to the public markets

8 years ago

After some stinging setbacks, a top analyst questions the high failure rate for Celgene's drug pipeline

8 years ago

Those open offices biopharma execs love so much? Most staffers hate them with a passion

8 years ago

AstraZeneca caps its big win in lung cancer with positive survival data for Imfinzi — and what a relief it is

8 years ago

BioMarin gets its shot at another blockbuster as FDA OKs rare disease drug pegvaliase

8 years ago

Magenta Therapeutics unveils plans to raise $100M in IPO weeks after a crossover round

8 years ago

Recro shares tank on FDA’s CRL; Prothena axes more than half of staff; Novo inks $200M deal with Epigen

8 years ago

Merck data and a tumbling stock price cost Armo's investors $320M-plus in Eli Lilly buyout

8 years ago

Brad Loncar's ASCO18 preview: Past ASCOs point to the top drugs that will soon elbow for the Oscars of cancer R&D

8 years ago

Rockwell's CEO refuses to be fired, kicking up brawl with board that halts the company's stock

8 years ago

AstraZeneca unveils its brand new open-office center in the Bay Area. Do you love it, or hate it?

8 years ago

Autoimmune biotech Kiniksa prices upsized $152M IPO as Scholar Rock bags $75M for preclinical SMA drug

8 years ago

Aptinyx looks to bring its NMDA pipeline to Nasdaq, filing for an $80 million IPO

8 years ago

This startup CEO swiftly gained $260M and a dream team of biotech backers — on both sides of the Pacific

8 years ago

Astellas shedding 600-plus jobs as CEO shakes up R&D and sales ops in restructuring

8 years ago

Oxford spinout grabs $9M A round for peptide platform; bluebird gets a 'breakthrough' at the FDA

8 years ago

New PhIII gives Esperion's CEO a chance to push back against a legion of critics — but can he win back investors?

8 years ago

Merck crushes Keynote-407 study in frontline lung cancer, hitting co-primaries and setting up another quick OK

8 years ago

First page Previous page 1033 1034 103510361037 1038 1039 Next page Last page